SEC Comment Letter 0000000000-23-003505 to VACCINEX, INC. (VCNX) (CIK 0001205922) (VCNX)
VACCINEX, INC. (VCNX) (CIK 0001205922)
Date: April 7, 2023 · CIK: 0001205922 · Accession: 0000000000-23-003505
AI Filing Summary & Sentiment
File numbers found in text: 333-271074
Letter
United States securities and exchange commission logo April 7, 2023 Maurice Zauderer, Ph.D. President and Chief Executive Officer Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Re:Vaccinex, Inc. Registration Statement on Form S-3 Filed April 3, 2023 File No. 333-271074 Dear Maurice Zauderer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William I. Intner
Show Raw Text
United States securities and exchange commission logo
April 7, 2023
Maurice Zauderer, Ph.D.
President and Chief Executive Officer
Vaccinex, Inc.
1895 Mount Hope Avenue
Rochester, New York 14620
Re:Vaccinex, Inc.
Registration Statement on Form S-3
Filed April 3, 2023
File No. 333-271074
Dear Maurice Zauderer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: William I. Intner